Key result
Serum cystatin C demonstrated higher sensitivity (90.8% vs 47.8%) and specificity (90.6% vs 78.1%) compared to serum creatinine for detecting early-stage chronic kidney disease (GFR < 80 mL/min/1.73 m2) in hypertensive patients.
Why the study?
Screening for early-stage chronic kidney disease in patients with hypertension remains controversial.
Does serum cystatin C improve the detection of early-stage chronic kidney disease compared to serum creatinine in patients with primary hypertension?
Cross-Sectional (n=304)
No
Does serum cystatin C improve the detection of early-stage chronic kidney disease compared to serum creatinine in patients with primary hypertension?
Serum cystatin C and its derived eGFR equations demonstrate significantly higher sensitivity and specificity than serum creatinine for detecting early-stage chronic kidney disease in patients with primary hypertension.
Answers are grounded in this paper and cite their sources.
May improve early CKD detection in hypertension over creatinine; leaves open need for prospective outcome validation.
Background: Hypertension is one of the most common diseases worldwide, especially in Viet Nam. Screening for early-stage chronic kidney disease (CKD) in patients with hypertension remains controversial. We aimed to analyze the sensitivity and specificity of serum cystatin C and serum creatinine in detecting early-stage kidney function loss as a complication in hypertensive patients. Material and methods: From January 2013 to October 2018, 304 patients first-time diagnosed with primary hypertension at University Medical Center Ho Chi Minh City participated in this cross-sectional study. Collected data includes anthropometric indicators, measured glomerular filtration rate (GFR) by plasma 99m Tc-diethylenetriaminepentaacetic clearance, serum cystatin C (ScysC), and serum creatinine (Scr). Results: ScysC level was significantly reciprocal correlation between renal radiography (r = 0.781, p < 0.001). The cutoff value for the identification of GFR < 80 mL/min/1.73 m 2 was ScysC > 1.06 mg/L with a sensitivity of 90.8% and specificity of 90.6%, AUC was 0.90. The sensitivity and specificity of ScysC for the identification of GFR < 70 mL/min/1.73 m 2 and GFR < 60 mL/min/1.73 m 2 was 96.6%, 100% and 98.8%, 99.3%, respectively. Among 14 estimated glomerular filtration formulas used in this study, eGFR-cysC-Filler-Lepage had the highest sensitivity and specificity for identifying GFR < 80 mL/min/1.73 m 2 (79.8% and 100%, respectively). eGFR-cysC-LeBrion had the highest sensitivity and specificity for the identification of GFR < 70 mL/min/1.73 m 2 and GFR < 60 mL/min/1.73 m 2 (97.6%, 96.9% and 100%, 97%; respectively). Conclusion: The sensitivity and specificity of ScysC were significantly higher than Scr. The eGFR-cysC-Filler-Lepage formula had the highest sensitivity and specificity in detecting the early stages of CKD.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2022) conducted a cross-sectional in Primary hypertension (n=304). Serum cystatin C vs. Serum creatinine was evaluated on Sensitivity for identification of GFR < 80 mL/min/1.73 m2. Serum cystatin C demonstrated higher sensitivity (90.8% vs 47.8%) and specificity (90.6% vs 78.1%) compared to serum creatinine for detecting early-stage chronic kidney disease (GFR < 80 mL/min/1.73 m2) in hypertensive patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: